KOL Strategy & Investigator Engagement
Clinical leadership drives trial performance and strengthens market adoption
Key Outcomes
Greater scientific visibility through publications and presentations
Clinical leadership that strengthens post-market evidence generation
Increased enrollment velocity and reduced activation delays
Stronger readiness for guideline influence and society engagement
Early engagement with key opinion leaders and the right mix of investigators is one of the highest-leverage decisions in MedTech clinical development. In practice, selecting the wrong investigators slows enrollment, weakens data quality, and limits downstream influence with value analysis committees and early adopter clinicians. Engaging the right clinical leaders early provides a dual benefit: stronger trial execution and a foundation for commercial adoption.
Our team builds structured KOL and investigator engagement plans that align scientific credibility, enrollment strategy, and long-term clinical advocacy.
CHALLENGES
When Clinical Leadership and Trial Strategy Are Misaligned
Across early-stage and international MedTech companies, the same issues often delay trial execution and weaken clinical influence
Limited access to KOLs who shape clinical guidelines and influence decision-making
Insufficient clarity on site selection criteria and investigator expectations
Overreliance on academic sites that enroll slowly
Lack of structured communication to maintain engagement throughout the trial
Weak alignment between target indications, endpoints, and investigators
No pathway to transition clinical leaders into advisory roles
These gaps reduce enrollment efficiency and limit the clinical influence necessary for successful U.S. adoption
OUR PROCESS
How We Develop KOLs and Investigators
UnifiMed aligns clinical leadership, enrollment performance, and long-term advocacy through a structured KOL and investigator strategy
Clinical Landscape & Influence Mapping
We map the clinical ecosystem that shapes credibility for your indication, identifying specialty-specific KOL networks, key societies and guideline bodies, publication leaders, investigator performance benchmarks, and centers with proven enrollment velocity. This defines the pool of clinicians who matter both scientifically and operationally
Targeted KOL & Investigator Selection
We prioritize KOLs and investigators based on indication fit, prior experience with similar technologies, enrollment history, operational capacity, and regional or national influence. Selection is driven by measurable trial-relevant criteria, ensuring each clinical leader can both execute and credibly represent the therapy
Engagement Workflows & Site Readiness
We convert interest into operational readiness through structured engagement workflows, including scientific discussions, protocol review, feasibility assessments, and coordinated contracting and budget processes. Ongoing operational touchpoints maintain momentum so investigators stay engaged and sites move predictably from interest to active enrollment
Scientific Advisory & Advocacy Development
We build advisory and scientific programs that deepen clinical commitment beyond enrollment, including endpoint-focused evidence discussions, presentation and publication pathways, and milestone-based communication plans. This positions investigators as long-term advocates who support trial execution, guideline influence, and early commercial adoption
Ready to Learn More?
Contact our team to discuss how we can support your KOL and investigator development